Skip to content
value.today
Sutro Biopharma Inc. logo

Sutro Biopharma Inc.

Total raised
$85 M
1 round on record
Latest round
$85 M
May 2018
First round on record
May 2018
Today
Went public
See the company page

Sutro Biopharma Inc. is listed today as Sutro Biopharma, Inc.: market value, financials and filings are on its company page.

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Sutro Biopharma Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2018$85 MNo. 1$50 to $250 million

Sutro Biopharma Inc.: Raise no. 1, May 2018

Investors in this round

15 investors had bought by the notice of Aug 8, 2018: 15 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 19 investors are named for Sutro Biopharma Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$85 M of $85 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • William J. Newell · Executive Officer, Director
  • Armen Bryan Shanafelt · Director
  • Daniel Bryan Petree · Director
  • Daniel J. Janney · Director
  • John G. Freund · Director
  • Joseph Bryan Lobacki · Director
  • Michael Bryan Dybbs · Director
  • Michael Bryan Ross · Director
  • Virgil Bryan Lawlis · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by William J. Newell, Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Aug 8, 2018. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Sutro Biopharma Inc. chose not to state its revenue in its newest notice of a funding round (Aug 2018).

    SEC Form D · Aug 2018

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Aug 2018

That is all the official record says: Sutro Biopharma Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Sutro Biopharma Inc. are on record.

Investors#

19 named in official filings. Open an investor to see everything it has backed.

Investors in Sutro Biopharma Inc.
InvestorKindAmountRoundRoleSource
Alta Partners Management VIII, LLCFund or asset managernot statednot statedHeld Series B, C, D and E preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Alta Partners VIII, L.P.Fund or asset managernot statednot statedHeld Series B, C, D and E preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Celgene Corp /de/Companynot statednot statedHeld Series C-2, D, D-2 and E preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Edward C. AlbiniPersonnot statednot statedHeld Series D preferred stock (Form 3, 2018)SEC Form 3
Ilsf III, LLCOthernot statednot statedHeld Series A, B, C, D and E preferred stock, 10% owner (Form 3, 2018)SEC Form 3
International Life Sciences Fund III Co-Investment, L.P.Fund or asset managernot statednot statedHeld Series A, B, C, D and E preferred stock, 10% owner (Form 3, 2018)SEC Form 3
International Life Sciences Fund III (GP), L.P.Fund or asset managernot statednot statedHeld Series A, B, C, D and E preferred stock, 10% owner (Form 3, 2018)SEC Form 3
International Life Sciences Fund III (LP1), L.P.Fund or asset managernot statednot statedHeld Series A, B, C, D and E preferred stock, 10% owner (Form 3, 2018)SEC Form 3
International Life Sciences Fund III Strategic Partners, L.P.Fund or asset managernot statednot statedHeld Series A, B, C, D and E preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Merck & Co., Inc.Fund or asset managernot statednot statedHeld Series E preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Merck Sharp & Dohme Corp.Companynot statednot statedHeld Series E preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Skyline Venture Management V, LLCVenture capitalnot statednot statedHeld Series C, D and E preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Skyline Venture Partners V LPVenture capitalnot statednot statedHeld Series C, D and E preferred stock, 10% owner (Form 3, 2018)SEC Form 3
SV Life Sciences Fund V (GP), LPFund or asset managernot statednot statedHeld Series A, B, C, D and E preferred stock, 10% owner (Form 3, 2018)SEC Form 3
SV Life Sciences Fund V LPFund or asset managernot statednot statedHeld Series A, B, C, D and E preferred stock, 10% owner (Form 3, 2018)SEC Form 3
SV Life Sciences Fund V Strategic Partners, L.P.Fund or asset managernot statednot statedHeld Series A, B, C, D and E preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Svlsf V, LLCOthernot statednot statedHeld Series A, B, C, D and E preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Trevor HallamPersonnot statednot statedHeld Series D preferred stock (Form 3, 2018)SEC Form 3
William J. NewellPersonnot statednot statedHeld Series C and D preferred stock, director (Form 3, 2018)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 15 investors.

Largest shareholders today

Institutions holding Sutro Biopharma, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Sutro Biopharma Inc.
NameRoleNamed in
William J. NewellExecutive officerAug 2018
Armen Bryan ShanafeltDirectorAug 2018
Daniel Bryan PetreeDirectorAug 2018
Daniel J. JanneyDirectorAug 2018
John G. FreundDirectorAug 2018
Joseph Bryan LobackiDirectorAug 2018
Michael Bryan DybbsDirectorAug 2018
Michael Bryan RossDirectorAug 2018
Virgil Bryan LawlisDirectorAug 2018
William J. NewellDirectorAug 2018
Armen G. ShanafeltDirectorJun 2018
Bryan G. LawlisDirectorJun 2018
Joseph G. LobackiDirectorJun 2018
Michael G. RossDirectorJun 2018

About

Company.

Went public since 2018. Its SEC number is that of a company listed on a stock exchange.